Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Drug Alcohol Depend ; 206: 107743, 2020 01 01.
Article in English | MEDLINE | ID: mdl-31801107

ABSTRACT

BACKGROUND: Given the rising incidence of opioid overdose in the United States, naloxone access is critical for high-risk populations, such as persons who inject drugs (PWID). Yet not all PWID have access to this life-saving antidote. With PWID in Michigan recruited via respondent driven sampling in 2017, after the 2016 standing order expanding naloxone availability through local pharmacies, we explored possible access disparities. METHODS: With 46 seeds recruited from agencies serving local PWID communities, we obtained a sample of N = 410 PWID from Southeast Michigan (n = 285 form urban Detroit, and 125 for suburban/rural areas outside Detroit). Participants completed questionnaires detailing socio-demographics, health history, substance use and treatment access, including naloxone. We used multiple logistic regression to examine the predictors of self-reported naloxone access based on participant characteristics (e.g., demographics, health status) and geography (urban vs. suburban/rural). RESULTS: Self-reported naloxone access differed significantly by location (urban = 18.3 %; suburban/rural = 41.9 %). In multivariable analyses, naloxone access was significantly associated with race, household income, employment, health insurance, recent homelessness, prescription opioid usage, Hepatitis A and C status, Hepatitis A vaccination, Hepatitis C testing, access to drug treatment and services, and hospital as the usual place of care. CONCLUSION: Despite recent policies to expand access, our results indicate that naloxone access among high-risk PWID is low. This warrants future research to identify effective channels to reduce barriers and increase naloxone access.


Subject(s)
Health Services Accessibility , Healthcare Disparities , Ill-Housed Persons , Naloxone/administration & dosage , Substance Abuse, Intravenous/drug therapy , Substance Abuse, Intravenous/epidemiology , Adult , Cross-Sectional Studies , Female , Health Services Accessibility/economics , Healthcare Disparities/economics , Hepatitis C/diet therapy , Hepatitis C/economics , Hepatitis C/epidemiology , Humans , Male , Michigan/epidemiology , Middle Aged , Naloxone/economics , Opioid-Related Disorders/diet therapy , Opioid-Related Disorders/economics , Opioid-Related Disorders/epidemiology , Risk Factors , Self Report , Substance Abuse, Intravenous/economics , Surveys and Questionnaires
2.
Food Chem ; 274: 900-906, 2019 Feb 15.
Article in English | MEDLINE | ID: mdl-30373026

ABSTRACT

Detarium microcarpum is a plant indigenous to Africa, which occurs naturally in many African countries, particularly in savannah regions. Its leaves and fruits are used mainly as food and as folk medicine. It has anti-diabetic, antioxidant, and hepatitis C inhibitor properties and has been traditionally utilised in cancer treatment. This review examines published work on the nutritional, pharmacological, and traditional uses of Detarium microcarpum. This plant may become valuable if the fruit, stems, roots, and leaves are extracted for nutraceutical purposes.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Antioxidants/pharmacology , Fabaceae/chemistry , Fabaceae/physiology , Hypoglycemic Agents/pharmacology , Africa , Antineoplastic Agents, Phytogenic/chemistry , Antioxidants/chemistry , Cholinesterase Inhibitors/chemistry , Cholinesterase Inhibitors/pharmacology , Fruit/chemistry , Hepatitis C/diet therapy , Humans , Hypoglycemic Agents/chemistry , Medicine, African Traditional , Nutritive Value , Plant Extracts/pharmacology , Plant Gums/chemistry , Plant Leaves/chemistry , Plant Roots/chemistry , Waste Disposal, Fluid/methods
3.
J Clin Gastroenterol ; 52(1): 55-59, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28617761

ABSTRACT

BACKGROUND: Hepatitis C virus (HCV) is a global medical health concern. Egypt has the highest HCV prevalence. Few studies have assessed the HCV prevalence rates among Egyptian-born expatriates. We sought to define the HCV prevalence Egyptian-born individuals residing in the Southern California area. PATIENTS AND METHODS: We screened Egyptian-born individuals in houses of worship in the Southern California area using a point of care test HCV antibody test. Results were confirmed by testing the blood for viral load. Demographic information including risk factors were also collected. Individuals were contacted with their results, and those found to be detectable HCV antibodies were referred for further testing and additional care. RESULTS: Three hundred twenty-six Egyptian expatriates from 7 houses of worship in Southern California were screened for the HCV infection. Most of the participants were screened at Coptic Churches. Nine of these individuals were found to be HCV infected (2.8%). We found an increased HCV seroprevalence in subjects were male and born in Egyptian urban areas. Five of the 9 subjects (56%) who tested positive were not baby boomers and only 2 of these 9 subjects (22%) had recognized Center for Disease Control risk factors. CONCLUSIONS: The HCV prevalence rate of Egyptian-born individuals living in the Southern California area was lower compared with the prevalence rate in the general Egyptian population, but higher than that seen in the general US population. The utility of using Center for Disease Control risk factors to define individuals at risk of HCV among Egyptian expatriates is not applicable.


Subject(s)
Hepacivirus/immunology , Hepatitis C/epidemiology , California/epidemiology , Egypt/ethnology , Female , Hepatitis C/blood , Hepatitis C/diet therapy , Hepatitis C/prevention & control , Hepatitis C Antibodies/blood , Humans , Male , Middle Aged , Prevalence , Seroepidemiologic Studies
4.
Liver Int ; 35(4): 1303-14, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25156780

ABSTRACT

BACKGROUND & AIMS: Branched-chain amino acids (BCAA) reduce the incidence of hepatocellular carcinoma (HCC) in patients with cirrhosis. However, the mechanisms that underlie these effects remain unknown. Previously, we reported that oxidative stress in male transgenic mice that expressed hepatitis C virus polyprotein (HCVTgM) caused hepatic iron accumulation by reducing hepcidin transcription, thereby leading to HCC development. This study investigated whether long-term treatment with BCAA reduced hepatic iron accumulation and oxidative stress in iron-overloaded HCVTgM and in patients with HCV-related advanced fibrosis. METHODS: Male HCVTgM were fed an excess-iron diet that comprised either casein or 3.0% BCAA, or a control diet, for 6 months. RESULTS: For HCVTgM, BCAA supplementation increased the serum hepcidin-25 levels and antioxidant status [ratio of biological antioxidant potential (BAP) relative to derivatives of reactive oxygen metabolites (dROM)], decreased the hepatic iron contents, attenuated reactive oxygen species generation, and restored mitochondrial superoxide dismutase expression and mitochondrial complex I activity in the liver compared with mice fed the control diet. After 48 weeks of BCAA supplementation in patients with HCV-related advanced fibrosis, BAP/dROM and serum hepcidin-25 increased and serum ferritin decreased compared with the pretreatment levels. CONCLUSIONS: BCAA supplementation reduced oxidative stress by restoring mitochondrial function and improved iron metabolism by increasing hepcidin-25 in both iron-overloaded HCVTgM and patients with HCV-related advanced fibrosis. These activities of BCAA may partially account for their inhibitory effects on HCC development in cirrhosis patients.


Subject(s)
Amino Acids, Branched-Chain/administration & dosage , Dietary Proteins/administration & dosage , Hepacivirus/metabolism , Hepatitis C/diet therapy , Iron/metabolism , Liver Cirrhosis/diet therapy , Liver/metabolism , Oxidative Stress , Polyproteins/metabolism , Viral Proteins/metabolism , Aged , Aged, 80 and over , Animals , Antioxidants/metabolism , Biomarkers/blood , Disease Models, Animal , Female , Ferritins/blood , Hepacivirus/genetics , Hepatitis C/blood , Hepatitis C/genetics , Hepatitis C/metabolism , Hepcidins/blood , Humans , Japan , Liver Cirrhosis/blood , Liver Cirrhosis/genetics , Liver Cirrhosis/metabolism , Male , Mice, Transgenic , Polyproteins/genetics , Reactive Oxygen Species/blood , Time Factors , Treatment Outcome , Viral Proteins/genetics
5.
Biol Trace Elem Res ; 152(2): 187-94, 2013 May.
Article in English | MEDLINE | ID: mdl-23412808

ABSTRACT

The use of natural remedies and pharmacological mineral supplements for liver disease treatment has a long history. In present study, the levels of selenium (Se) and zinc (Zn) were determined in biological samples (serum and whole blood) of female hepatitis C patients (n = 132), age ranged 30-45 years, before and after 30 days treatment with herbal/pharmaceutical supplements. For comparative study, 128 age-matched female subjects, residing in the same residential areas and have socioeconomic status, were selected as referents. The Se and Zn in supplements, blood, and sera were determined by atomic absorption spectrometry. It was observed that Zn and Se in blood and serum samples of viral hepatitis C (HCV) patients were reduced in the range of 28.6-39 % and 24-36 %, respectively, as compared to those of referents. After herbal/pharmaceutical supplementations, 20.6-25.0 and 9.15-13.2 % of Zn and 10.6-12.1 and 19.6-21.4 % of Se were enhanced in sera and blood samples of HCV patients, respectively. The resulted data indicated that the levels of Se and Zn in addition to some biochemical parameters were improved in HCV patients after herbal/pharmaceutical supplementation. The effects of both supplements were not significantly different (p > 0.05).


Subject(s)
Hepatitis C/blood , Selenium/blood , Zinc/blood , Adult , Dietary Supplements , Female , Hepatitis C/diet therapy , Hepatitis C/drug therapy , Humans , Middle Aged , Trace Elements/blood
6.
Int J Cancer ; 115(2): 290-5, 2005 Jun 10.
Article in English | MEDLINE | ID: mdl-15688396

ABSTRACT

To determine if the risk of hepatocellular carcinoma (HCC) is reduced by consumption of soya foods, we conducted a case-control study within a cohort of Japanese A-bomb survivors. We compared the prediagnosis consumption of isoflavone-rich miso soup and tofu to HCC risk, adjusting for hepatitis B (HBV) and C (HCV) viral infections, the major HCC risk factors in this population. The study included 176 pathologist-confirmed cases of HCC diagnosed in 1964-1988 and 560 controls who died of diseases other than liver cancer. We examined dietary information collected at least 2 years before diagnosis or death and tissue-based measures of viral hepatitis. Using logistic regression, crude ORs were 0.5 (95% CI 0.29-0.95) and 0.5 (95% CI 0.20-0.99) for high vs. low miso soup and tofu intake, respectively. Adjusting for year of birth, sex, HBV, HCV and other factors, the OR for miso soup was unchanged at 0.5 (95% CI 0.14-1.55), and miso results were similar when ORs were recalculated separately for earlier and later birth cohorts to assess consistency of results. The adjusted OR for tofu was 0.9 (95% CI 0.20-3.51). We also found a statistically significant (p < 0.0001) interaction between sex and HCV, with risk of HCC being substantially higher for women. We conclude that consumption of miso soup and other soya foods may reduce HCC risk.


Subject(s)
Carcinoma, Hepatocellular/diet therapy , Hepatitis B/diet therapy , Hepatitis C/diet therapy , Liver Neoplasms/diet therapy , Soy Foods , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/etiology , Case-Control Studies , Cohort Studies , Feeding Behavior , Hepacivirus/isolation & purification , Hepatitis B/complications , Hepatitis B/epidemiology , Hepatitis B virus/isolation & purification , Hepatitis C/complications , Hepatitis C/epidemiology , Humans , Japan , Liver Neoplasms/epidemiology , Liver Neoplasms/etiology , Risk Factors
7.
Antiviral Res ; 63 Suppl 1: S11-8, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15450381

ABSTRACT

Surrogate markers are an important component in the process of investigating management and prevention strategies, and for increasing understanding of viral diseases. The importance of surrogate markers and applied statistical models is particularly true for HIV. For HIV infection, the development of such methods provides new approaches for evaluation of HIV therapies and vaccines, and for the study of HIV transmission and its pathogenesis. The complex natural history of hepatitis B infection demonstrates that viral load is not the only predictor of transmission of this virus; for hepatitis C infection, viral load per se is not a prognostic factor for disease progression, but cumulative viral load may affect the outcome, and therapy is aimed at eliminating active viral replication.


Subject(s)
HIV Infections/transmission , HIV/physiology , Hepacivirus/physiology , Hepatitis B virus/physiology , Hepatitis B/transmission , Hepatitis C/transmission , Biomarkers , CD4 Lymphocyte Count , Disease Transmission, Infectious/prevention & control , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Infections/virology , Hepatitis B/drug therapy , Hepatitis B/epidemiology , Hepatitis B/virology , Hepatitis C/diet therapy , Hepatitis C/epidemiology , Hepatitis C/prevention & control , Hepatitis C/virology , Humans , Infectious Disease Transmission, Vertical/prevention & control , Viral Load , Virus Replication
8.
J Coll Physicians Surg Pak ; 13(8): 477-82, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12921690

ABSTRACT

Hepatitis-C is a silent epidemic. Proper measures are required to be reinforced to prevent the spread of this disease. Combination treatment with interferon and ribavirin has been holding ground in the battle to fight this disease. The number of responders to hepatitis-C has increased even more with the advent of pegylated interferon. The treatment has to be well planned and a pre-treatment evaluation is mandatory. Similarly, during treatment, proper monitoring of the patients is of utmost importance. However, there are treatment limits for each genotype which must be respected. There is no single approach for non-responders, hence, this situation continues to be a therapeutic dilemma. Use of interferon in compensated cirrhosis has its own limitations while its role in decompensated cirrhosis remains experimental only. Liver biopsy has its importance in proper evaluation of the patient. Acute hepatitis-C is rare but current data suggests that active treatment is as much necessary for acute as it is for chronic hepatitis.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C/diet therapy , Counseling/methods , Hepatitis C/therapy , Humans
9.
Vopr Pitan ; (1): 10-3, 1998.
Article in Russian | MEDLINE | ID: mdl-9606859

ABSTRACT

Acid mussel hydrolisate MIGI-K LP is a food product, and a medical and prophylactic preparation containing a full set of irreplaceable amino acids (with the exception of thriptophane), essential fatty acids, macro- and microelements. MIGI-K LP can be used as a foot additive which improves the taste and increases the food qualities of the product, and as a medical preparation against some diseases.


Subject(s)
Bivalvia/metabolism , Food Additives/isolation & purification , Free Radical Scavengers/isolation & purification , Protein Hydrolysates/isolation & purification , Radiation-Protective Agents/isolation & purification , Shellfish , Adolescent , Adult , Aged , Amino Acids/analysis , Animals , Child , Child, Preschool , Fatty Acids/analysis , Gastrointestinal Diseases/diet therapy , Hepatitis B/diet therapy , Hepatitis C/diet therapy , Humans , Infant , Middle Aged , Quality Control , Trace Elements/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...